Objective: The aim of this work was to evaluate the impact of stereotactic radiosurgery/fractionated stereotactic radiotherapy with the Cyberknife system on local disease control, clinical outcome and toxicity in patients with meningioma, according to the site and histological grade of lesion. From January 2013 to April 2017, 52 patients with intracranial meningiomas were treated with the Cyberknife system. Twenty-four patients had undergone previous surgery: 38% gross total resection, 10% subtotal resection; 27 patients underwent no surgery; 22 patients had a recurrence of meningioma. Methods: Radiosurgery was used for lesions smaller than 2 cm, stereotactic radiotherapy for lesions larger than 2 cm, or smaller but close to a critical site such as the optical chiasm, optic pathway or brainstem. Results: Local control and clinical outcomes were analysed. Median follow-up was 20 months: six patients died, one after re-surgery died from post-surgical sepsis, three from heart disease. Progression-free survival had a mean value of 38.3 months and overall survival of 41.6 months. We evaluated at 12 months 28 patients (100% local control); at 24 months 19 patients (89% local control); at 36 months nine patients (89% local control). At baseline, 44/52 patients (85%) were symptomatic: 19 visual disorders, 17 motor disorders, six hearing disorders, 10 headache and six epilepsy. Visual symptoms remained unchanged in 52%, improved in 32%, resolved in 16%. Headache was improved in 40%, resolved in 10%, unchanged in 50%. Epilepsy was resolved in 17%, unchanged in 33%, worsened in 33%. Conclusions: Stereotactic radiosurgery/fractionated stereotactic radiotherapy with Cyberknife provides a good local disease control, improving visual, hearing and motor symptoms.
Introduction
Meningiomas are the most common benign intracranial (90-95%) tumours, and are usually located at the cerebral convexity and falx, cerebellar tentorium, pontocerebellar angle and sphenoid region, mostly with a good prognosis and up to 80% of patients surviving at 5 years. 1 According to the histomorphological World Health Organization (WHO) classification, meningiomas are categorised into three groups: common type (grade I), atypical meningioma (grade II) and anaplastic type (grade III). 2 WHO grade II/III meningiomas have recurrence rates between 29-52% and 50-94%, respectively, due to parenchymal invasion or to the high risk of residual tumour cells after surgery. [3] [4] [5] [6] [7] [8] [9] [10] [11] This higher recurrence rate is closely related to a shorter overall survival (OS). 8 The choice of treatment is guided by the medical history of the patient, severity of symptoms, histological grade, site of lesions and risks/benefits ratio. Surgery is the primary treatment, with site, histological grade and radical surgery being considered the main prognostic factors. Adjuvant radiotherapy improves local control for atypical or malignant meningiomas, mostly of the skull base, pontocerebellar angle or cavernous sinus. A total dose of 54 Gray (Gy) in conventional fractionated radiation therapy (1.8-2.0 Gy per fraction) is the usual treatment choice after subtotal resection or recurrent tumours, improving local control. [12] [13] [14] [15] [16] [17] At present, thanks to the evolution in radiation therapy technology, stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) represent a viable alternative in selected cases, providing a local control of 97% in the first-line treatment or recurrence of grade I meningiomas, 50% in grade II meningiomas and 17% in grade III meningiomas. [18] [19] [20] [21] [22] SRS (12) (13) (14) (15) (16) (17) (18) Gy in a single fraction), as primary treatment for small meningiomas or as adjuvant treatment for residual disease, showed excellent results, with the same local control rate of both conventional radiation therapy and surgery. [23] [24] [25] [26] The Cyberknife (Accuray Inc., Sunnyvale, CA, USA) has been utilised to treat a wide variety of intracranial tumours, such as meningiomas. 27 The aim of our observational study was to determine the impact of treatment with the use of SRS/FSRT with the Cyberknife system of patients with intracranial meningiomas on outcome in terms of local control of the neoplasm, and its symptomatic resolution according to location, size and histological grade.
Patients and methods
From January 2013 to April 2017, 52 patients, 28 women and 27 men, with a median age 62 years, affected by intracranial meningiomas, were treated with the Cyberknife system in our Department of Radiation Oncology. The patients' characteristics are shown in Table 1 .
Twenty-four patients (46%) had undergone previous surgery: 19 (36%) received gross total resection and five (10%) subtotal resection. Thirty-four were treated without pathological confirmation. Twenty-eight (54%) patients underwent primary radiotherapy, three (6%) on post-surgery residual and 21 patients (40%) for recurrence. The lesions were divided according to the tumour size (27% < 2 cm, 27% 2-3 cm, 46% > 3 cm) and the site (13% angle ponto-cerebellar, 8% tentorium, 15% falx/ parasagittal, 19% convexity, 45% skull base) ( Table 1) .
All patients had been assessed at baseline with contrast-enhanced brain magnetic resonance imaging (MRI). T1-T2 weighted with thin section (1 mm) was customised with a thermoplastic mask and acquired a thin slice (1 mm) contrast-enhanced simulation computed tomography (simul-CT): identification and delineation of volumes (target and organs at risk; OARs) were performed on simul-CT scans fused with MRI images.
OARs are considered whole brain, left and right (L-R) eye, L-R lens, L-R optic nerve, optic chiasm, pituitary gland, brainstem, L-R cochlea, spinal cord. Clinical target volume (CTV) was the same volume as gross tumour volume; planning target volume was the CTV plus a 2 mm margin in all directions.
In planning the treatment, meningiomas were assumed to have a a/b ratio equal to 3: indeed, we selected the prescription dose and fractionation according to the size and site of the lesions. A single fraction was used to treat lesions less than 2 cm, while FSRT was prescribed to treat lesions greater than 2 cm or less than 3 cm, but too close to a critical site, such as the optical chiasm or angle pontocerebellar.
In order to evaluate dose constraints to OARs, we considered the indications of the University of Texas Southwestern (Timmerman) investigators 28 ( Table 2) . In the table are the main characteristics of the patients, the type of surgery and radiotherapy, the purpose of the treatments, the site of meningiomas, the diameter, the total dose delivered and the number of fractions.
Treatment planning was performed with the Multiplan Software (Accuray Inc., Sunnyvale, CA, USA).
All treatments were delivered with the Cyberknife system, a frameless image-guided robotic radiosurgery system. 29 This system consists of a small linear accelerator (LINAC, 6 MV Photon) mounted on the robotic arm, which moves around the patient to provide a large number of beams from 1200 different positions. Verification X-rays are taken during treatment and are compared with the digital reconstructed radiography (DRR) of simul-CT scans to change the position of the robot according to the movement of the patient. Patients were evaluated with clinical and instrumental follow-up with brain contrast-enhanced MRI with thin section (1 mm), the first time 2 months after radiotherapy, then every 6 months for the first 3 years and annually for the next 5 years. For malignant or recurrent meningioma, a more intensive follow-up was carried out, with follow-up every 2 months for the first 3 years and then every 6 months. Clinical outcome was evaluated by analysing symptoms evolution. Local control was reported according to RECIST criteria. No further approval of the ethics committee was required for this study, because patients gave written informed consent approved by the ethics committee allowing the use of their data and images for scientific studies and evaluations.
Results
All 52 patients completed the programmed treatment with the prescribed dose: in 28 patients, radiotherapy was performed with a radical intent, in three patients as an adjuvant treatment and in 21 patients as a retreatment for recurrence (four of these were treated previously with radiotherapy, two with Gammaknife, one with Cyberknife and one with 3DCRT). One patient was treated twice for progressive disease at the same site. Five patients (10%) were treated with single fraction SRS (10-15 Gy), 18 patients (35%) with FSRT in three fractions (15-21 Gy), 29 patients (56%) with FSRT in five fractions (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , two patients (4%) with FSRT in six fractions (24) (25) (26) , and one patient (2%) with FSRT in four fractions (20 Gy). The prescription isodose was 80% for all SRS/FSRT plans. The median tumour coverage was 98.50% (96.51-99.49). The median value of the homogeneity index was 1.25, and the median value of the new conformity index was 1.16. In all patients, dose constraints for all contoured OARs were respected: 47 patients had evaluable follow-up (median 20 months, range 2-48); 28 patients had a follow-up of at least 12 months; 19 patients at least 24 months. Six patients died, two from progression of disease after 5 and 8 months after radiotherapy: one patient after 27 months from radiotherapy re-underwent surgery and died 4 months later from post-surgical sepsis; three patients died from heart disease. At 12 months of follow-up, 28 patients were evaluated for local control: 100% obtained local control, 20 (71%) with stable disease, eight (29%) with partial reduction of tumour. At 24 months of follow-up, we evaluated 20 patients, with 85% local control rate, 12 (60%) with stable disease, five (25%) with partial reduction of tumour; three patients (15%) experienced disease progression. Nine patients had 36 months follow-up: 89% were in local control (Figure 1 ), six (67%) with stable disease, two (22%) with partial reduction of tumour; only one patient (11%) had a progression of disease.
Progression-free survival (PFS) had a mean value of 38.3 months (95% confidence interval (CI) 33.15-43.5), and OS had a median value of 41.6 months (95% CI 26.12-57.1) (Figure 2 ): median PFS could not be achieved, because of too many patients not progressing.
Regarding the volume changes of the lesion after radiotherapy, tumour volume decreased in 11 patients (23%), with stable disease for a median time of 20 (4-36) months after the end of treatment, 45 patients (96%) reached stability at a median time of 18 months, and increased in eight patients (17%) at a median time of 20 months. In Table 1 we reported the data on the original tumour volume. We calculated the PFS and OS in relation to the original volume, but did not have significant data regarding the assessment of the reduction in tumours. At this time, the size and shape of the injuries do not allow us to give conclusive data. With the enrollment of a greater number of patients, we will try to consider this aspect and try to stratify in this regard. The PFS and OS based on the location of the tumour did not provide significant data.
We assessed the symptoms of patients compared to the pre-radiotherapy condition: at baseline, 44/52 patients (85%) were symptomatic, mostly suffering from visual disorders (19 patients, 43% of symptomatic patients), motor disorders in 17 patients (39% of symptomatic patients), hearing disorders in six patients (14%), OARs: organs at risk. Constraints used in planning radiotherapy with Cyberknife system for meningioma patients.
headache in 10 patients (23% of symptomatic patients) and epileptic seizures in six patients (14% of symptomatic patients). No acute neurological symptoms related to radiotherapy were reported. A generally positive trend, with symptom relief, was observed after radiotherapy, particularly in six patients who achieved improvement and three patients a complete resolution; 10 patients reached stability of visual functions. For motor disorders, we observed an improvement in two patients, complete resolution in one patient, stability in 11 patients, worsening in three patients and new onset in three patients. For hearing disorders, we observed an improvement in two patients, resolution in one patient, new onset in three patients, worsening in one patient and stability in two patients. An improvement of headache was observed in one patient, complete resolution in four, stability of symptoms in five and new onset in two patients. For epilepsy a complete resolution was observed in one patient, improvement in one, stability in two, worsening in two and new onset in one patient (Table 3) .
In Table 3 are reported mayor symptoms referred, and the evolution during and after radiotherapy.
We noted a general improvement of symptoms (reduction or resolved) in 57% of cases, stability in 33%, worsening in 10%. Regarding the image of dose distribution and plan evaluation, in Figure 3 we show four cases of meningiomas near critical structures, such as the optic nerve, chiasm, brainstem.
In Figure 4 we see two cases of meningioma near to visual structures, the first is a case of a patient with a single meningioma, the second case is a patient with multiple meningiomas. The images show dose distribution. On the left we see the reduction of lesions evaluated with contrast-enhanced brain magnetic resonance imaging to the subsequent follow-up.
In Figure 5 , a patient with a meningioma parasellar was evaluated.
He did not undergo surgery, referring symptoms such as epilepsy and decreasing of visus; therefore, he was treated with 25 Gy in five fractions with the Cyberknife system, and after 6 months we detected reduction of tumour volume with improvement of vision and complete resolution of epileptic seizures, with stable disease at 24 months and further reduction of tumour volume.
Discussion
Cyberknife is a new technological tool combining a mobile linear accelerator mounted on a robotic arm with an image-guided robotic system: patients' position and motion are measured with two diagnostic X-ray cameras and communicated in real time to the robotic arm for beam targeting and patient motion tracking. Treatments are delivered in one or a few fractions, achieving the same level of targeting precision as frame-based SRS. 1 Hypofractionated regimens can be used for patients with tumours involving the optic apparatus, and therefore not suitable for radiosurgery due to tumour site being close to critical organs. [2] [3] [4] [5] [6] [7] SRS is usually reserved for locations where surgical risk is expected to be higher, and is considered suitable for meningiomas with a maximum diameter less than 3-4 cm, with a distinct margin, minimal oedema and adequate distance from critical normal tissue. Radiosurgical doses between 12 and 18 Gy have been used for meningiomas: a similar 5-year tumour control rate in the range of 90-95% has been observed with doses of 15-16 Gy or 12-14 Gy. Several studies demonstrated that tumour control decreases and radiation toxicity increases for superficial lesions, as well with increasing tumour size. 1, 10 Radiation-induced toxicity has been shown in up to 40% after SRS, being represented by either transient or permanent neurological symptoms. Complications, such as epilepsy, internal carotid occlusion and hypopituitarism have been rarely reported (less than 1-2%). 11 Atypical or malignant meningioma are usually irradiated after complete surgical excision. 2 Modern radiotherapy techniques require correct determination of tumour localisation and extension; therefore, MRI, in addition to its prevalent role in tumour staging, evaluation of response to therapy and assessment of recurrence, plays a pivotal role in delineation of the target volume in the radiotherapy treatment planning process. In this sense, the CT-MRI image fusion provides a better discrimination between tumour tissue with infiltration of boundaries and adjacent normal structures, enabling better target delineation for radiotherapy treatment planning. 12 This approach is useful not only for primary radiotherapy treatment of tumours, but also for re-treatments, being the system able to distinguish changes due to recurrent cancer or post-treatment fibrosis. [13] [14] [15] [16] Regarding indications for microsurgical removal or radiosurgery, as well as combination strategies using the two treatment modalities, there are indications on a complete microsurgical removal when a low probability of complication exists: combination of microsurgery and radiosurgery when complete removal would be accompanied by a high rate of complications is indicated. 23, [30] [31] [32] [33] [34] [35] [36] For lesions smaller than 2 cm clinically and radiologically stable, observation is recommended; for tumours smaller than 3 cm confined to the cavernous sinus and distant from the optic pathways and brainstem, primary radiosurgery is a viable option. For tumours greater than 3 cm attached to or compressing the optic pathways, radical surgery or decompression, followed by radiosurgery, are indicated.
Sometimes, radiotherapy is the only opportunity of treatment in these patients, such as in meningiomas arising from the optic nerve; therefore, great accuracy is required, in order to achieve not only tumour control, but also the preservation of visual function. The small number of fractions with the Cyberknife (up to five) has been advocated by Shrieve et al. 37 as an effective way to decrease visual complications in SRS of parasellar meningiomas. Fractionated schemes were extended to tumours close to other critical structures, such as the brainstem, cranial nerves, motor, visual and language cortex. Regarding visual function, lesions involving the anterior angle of the chiasm, the point at which the optic nerve passes into and forms the chiasm, may show a junctional scotoma; lesions which affect the body of the chiasm produce the typical bitemporal hemianopia, while lesions within the posterior aspect of the body of the chiasm produce bitemporal hemianopic scotomas. 38, 39 Lo et al. 40 reported a similar 3-year local control of 94% in 35 patients treated with SRS and in 18 patients with large tumours treated with FSRT. Tumours less than 3 cm and more than 3-5 mm away from radiosensitive structures, such as the optic chiasm or brainstem, were treated with SRS; FSRT was employed by others: Minniti et al. recommended FSRT for skull base tumours greater than 3 cm, in close proximity to the optic chiasm (less than 3-5 mm) or compressing the brainstem and with irregular margins. 20 Regarding the symptoms, Colombo et al. detected, in a report involving 208 patients, no change in 74%; 16% had symptom relief improvement between 3 and 18 months after irradiation; 3% of patients experienced worsening of clinical symptoms. Treatment failures seem to be unrelated to the fractionation scheme, or to tumour dimensions. Median survivals were not calculated due to the paucity of the events in the sample under consideration. 17 Conti et al. evaluated 64 patients and found in 20% of patients visual field or acuity was significantly improved after radiotherapy treatments; no tumour progressed at a median follow-up of 57.5 months and no patient developed new pituitary function deficits at the latest follow-up. Two of three patients had partial improvement of the third nerve deficits presenting preoperatively. Two patients (8%) complained of transient trigeminal neuralgia 6-12 months after treatment. 41 Oermann et al. 27 evaluated 38 patients: 63.2% showed neurological symptoms prior to therapy. After SRS, they observed complete resolution of neurological symptoms in 58.3%, unchanged symptoms in 33.3%, and recurrence of symptoms after initial improvement in 8.3%. Only one patient (2.6%) developed a new deficit, namely facial numbness, immediately after radiation, which resolved after a few days. Otherwise, no new neurological deficits were observed after SRS. Compared with data of these authors, our results confirm the effectiveness of this type of treatment for meningiomas; actually, we noted an improvement of symptoms in 57% of cases, stability in 33% and worsening in 10% (Table 4) . We attempted to establish if clinical variables, such as gender, surgery (no surgery vs. gross total surgery vs. sub-total surgery), radiotherapy (primary radiotherapy vs. adjuvant radiotherapy vs. radiotherapy on recurrence), meningioma characteristics (number, site, diameter), dose and fractions, affected patients' survival, but none of them showed a statistically significant association with PFS or OS (data not shown), also due to the paucity of the events in the sample under consideration.
Visual symptoms, affecting 19 patients before treatment, remained unchanged in 52%, improved in 32%, but of note, there was complete resolution in 16%. Headache, observed in 10 patients, improved in 40%, completely resolved in 10%, while in half of the patients it did not significantly change. Epileptic seizures disappeared in 17%, 33% were unchanged and 33% got worse. Of note, hearing symptoms detected in six patients improved in 33% and completely disappeared in the other 17%; speaking disorders detected in a patient were resolved entirely.
In conclusion, our experience confirms that SRS/FSRT with Cyberknife offer particular benefits to patients with large tumours, or located in critical sites, and allow good disease control, improving, in a limited number of patients, visual, hearing and motor symptoms. 
